 |
|
|
| |
The Pharmacokinetic Interactions of HCV Protease Inhibitor TMC435 with Rilpivirine, Tenofovir, Efavirenz or Raltegravir in Healthy Volunteers
|
| |
| |
Reported by Jules Levin
19th Conference on Retroviruses and
Opportunistic Infections
Seattle, WA March 5 - 8, 2012
S Ouwerkerk-Mahadevan,1 V Sekar,2 M Peeters,1 and M Beumont-Mauviel1
1 Janssen Research and Development, Beerse, Belgium;
2Janssen Research and Development, Titusville, NJ, USA
|
| |
|
|
|
|
|
